Sanofi's Tzield Receives FDA Approval for Diabetes Treatment

Dow Jones06-13

By Connor Hart

Sanofi secured accelerated approval from the Food and Drug Administration for its drug Tzield to be used in the treatment of people with the autoimmune and progressive nature of stage 3 type 1 diabetes

The company said Friday that the therapy can delay the decline in endogenous insulin production in children between the ages of eight and 17, who have recently been diagnosed with stage 3 type 1 diabetes.

"Approximately 64,000 people are diagnosed with T1D every year," said Aaron Kowalski, chief executive of Breakthrough T1D. "We are excited that the approval of Tzield in this indication provides a treatment option for certain patients diagnosed in stage 3 T1D, which is when many start experiencing common symptoms of the disease."

Sanofi said the treatment has previously received approvals in the U.K., European Union, China, Australia, Canada, Israel, Saudi Arabia, the United Arab Emirates, Kuwait, Brazil and Switzerland.

Regulatory reviews are ongoing in other jurisdictions around the world, it added.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

June 12, 2026 18:41 ET (22:41 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2643215430?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-13 06:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643215430","market":"other","top_or_hot":-1,"title":"Sanofi's Tzield Receives FDA Approval for Diabetes Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> secured accelerated approval from the Food and Drug Administration for its drug Tzield to be used in the treatment of people with the autoimmune and progressive nature of stage 3 type 1 diabetes \n</p>\n<p>\n  The company said Friday that the therapy can delay the decline in endogenous insulin production in children between the ages of eight and 17, who have recently been diagnosed with stage 3 type 1 diabetes. \n</p>\n<p>\n  \"Approximately 64,000 people are diagnosed with T1D every year,\" said Aaron Kowalski, chief executive of Breakthrough T1D. \"We are excited that the approval of Tzield in this indication provides a treatment option for certain patients diagnosed in stage 3 T1D, which is when many start experiencing common symptoms of the disease.\" \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> said the treatment has previously received approvals in the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>., European Union, China, Australia, Canada, Israel, Saudi Arabia, the United Arab Emirates, Kuwait, Brazil and Switzerland. \n</p>\n<p>\n  Regulatory reviews are ongoing in other jurisdictions around the world, it added. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 12, 2026 18:41 ET (22:41 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi's Tzield Receives FDA Approval for Diabetes Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi's Tzield Receives FDA Approval for Diabetes Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-13 06:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> secured accelerated approval from the Food and Drug Administration for its drug Tzield to be used in the treatment of people with the autoimmune and progressive nature of stage 3 type 1 diabetes \n</p>\n<p>\n  The company said Friday that the therapy can delay the decline in endogenous insulin production in children between the ages of eight and 17, who have recently been diagnosed with stage 3 type 1 diabetes. \n</p>\n<p>\n  \"Approximately 64,000 people are diagnosed with T1D every year,\" said Aaron Kowalski, chief executive of Breakthrough T1D. \"We are excited that the approval of Tzield in this indication provides a treatment option for certain patients diagnosed in stage 3 T1D, which is when many start experiencing common symptoms of the disease.\" \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> said the treatment has previously received approvals in the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>., European Union, China, Australia, Canada, Israel, Saudi Arabia, the United Arab Emirates, Kuwait, Brazil and Switzerland. \n</p>\n<p>\n  Regulatory reviews are ongoing in other jurisdictions around the world, it added. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 12, 2026 18:41 ET (22:41 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNYNF","symbol_name":"Sanofi","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2643215430","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2643215430","pubTimestamp":1781304060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Sanofi secured accelerated approval from the Food and Drug Administration for its drug Tzield to be used in the treatment of people with the autoimmune and progressive nature of stage 3 type 1 diabetes. The company said Friday that the therapy can delay the decline in endogenous insulin production in children between the ages of eight and 17, who have recently been diagnosed with stage 3 type 1 diabetes.\"Approximately 64,000 people are diagnosed with T1D every year,\" said Aaron Kowalski, chief executive of Breakthrough T1D. \"We are excited that the approval of Tzield in this indication provides a treatment option for certain patients diagnosed in stage 3 T1D, which is when many start experiencing common symptoms of the disease.\". Sanofi said the treatment has previously received approvals in the U.K., European Union, China, Australia, Canada, Israel, Saudi Arabia, the United Arab Emirates, Kuwait, Brazil and Switzerland.Regulatory reviews are ongoing in other jurisdictions around the w","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNYNF":"Sanofi","BK4007":"制药","BK4588":"碎股","BK4585":"ETF&股票定投概念","LABU":"三倍做多标普生物-Direxion","SNY":"赛诺菲安万特","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC"},"translate_title":"赛诺菲的Tzield获得FDA批准用于糖尿病治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":0.9,"SNYNF":1.5,"LABU":1.5},"content_text":"By Connor Hart \n\n\n \n\n\nSanofi secured accelerated approval from the Food and Drug Administration for its drug Tzield to be used in the treatment of people with the autoimmune and progressive nature of stage 3 type 1 diabetes \n\n\n  The company said Friday that the therapy can delay the decline in endogenous insulin production in children between the ages of eight and 17, who have recently been diagnosed with stage 3 type 1 diabetes. \n\n\n  \"Approximately 64,000 people are diagnosed with T1D every year,\" said Aaron Kowalski, chief executive of Breakthrough T1D. \"We are excited that the approval of Tzield in this indication provides a treatment option for certain patients diagnosed in stage 3 T1D, which is when many start experiencing common symptoms of the disease.\" \n\n\nSanofi said the treatment has previously received approvals in the U.K., European Union, China, Australia, Canada, Israel, Saudi Arabia, the United Arab Emirates, Kuwait, Brazil and Switzerland. \n\n\n  Regulatory reviews are ongoing in other jurisdictions around the world, it added. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 12, 2026 18:41 ET (22:41 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643215430","isCrawlerRequest":true}